IQWiG finds no proven added benefit for adjuvant cemiplimab in high-risk cutaneous squamous cell carcinoma
IQWiG dossier assessment A25-155, published on 16 March 2026, concluded that added benefit of adjuvant cemiplimab is not proven in high-risk cutaneous squamous cell carcinoma because available C-POST follow-up is too short for robust recurrence-focused interpretation.
Cross-domain NMA transitivity stress-testing: a March 2026 playbook for decision teams
Recent PubMed network meta-analysis publications across pharmacotherapy, surgery, and procedure-plus-medication pathways show why decision teams need explicit transitivity stress tests before converting rank outputs into reimbursement narratives.
Model-based treatment-duration NMA is becoming submission-critical: a governance playbook for evidence teams
New March 2026 publications show model-based duration-response network meta-analysis moving into practical evidence-generation workflows, requiring earlier protocol governance and tighter clinical-economic assumption alignment.
NCPE withholds reimbursement support for first-line amivantamab regimen pending stronger cost effectiveness
NCPE completed its full assessment on 10 March 2026 and recommended against reimbursement of amivantamab with carboplatin and pemetrexed for first-line EGFR exon 20 insertion NSCLC unless cost effectiveness improves.
Outcome-measurement heterogeneity is now a first-order ITC and NMA submission risk
A 15 March 2026 meta-analytic review reports rising outcome-measurement heterogeneity and measurable treatment-estimate shifts across depression psychotherapy trials. For HTA teams, the immediate operational response is endpoint governance by design: protocol-level mapping rules, instrument-stratified sensitivity plans, and audit-traceable assumption control across ITC, MAIC, and NMA workflows.
NICE final draft recommendation for fezolinetant reshapes evidence expectations for non-hormonal menopause care
NICE final draft guidance recommends fezolinetant for moderate to severe vasomotor symptoms when hormone replacement therapy is unsuitable, drawing on DAYLIGHT and SKYLIGHT trial evidence plus uncertain but decision-informing indirect comparator modelling.
NICE TA1121 recommends acoramidis and formalises a comparator-bridge evidence standard in transthyretin cardiomyopathy
NICE recommended acoramidis for transthyretin amyloidosis with cardiomyopathy on 14 January 2026, using indirect comparative evidence to position acoramidis against tafamidis in routine NHS use.
New editorial: SMC2915 non-submission outcome for pembrolizumab in pleural mesothelioma exposes a critical dossier-readiness failure
https://www.mattheneus.com/editorial/smc-pembrolizumab-smc2915-non-submission-mesothelioma-2026-03-15#HTA #EvidenceSynthesis #Pharma
SMC2915 non-submission outcome for pembrolizumab in pleural mesothelioma exposes a critical dossier-readiness failure
SMC published a non-recommendation for pembrolizumab combination therapy in unresectable non-epithelioid malignant pleural mesothelioma on 9 March 2026 due to non-submission by the marketing authorisation holder.
SMC accepts Alyftrek for restricted NHSScotland use, with evidence lineage anchored in active-comparator CFTR-modulator studies
On 9 March 2026, SMC accepted vanzacaftor/tezacaftor/deutivacaftor for restricted use in NHSScotland for people aged 6 years and older with at least one F508del mutation, with clinical lineage drawn from European Medicines Agency direct comparative study evidence.
EMA backs Xolremdi for WHIM syndrome under exceptional-circumstances pathway after placebo-controlled evidence review
At its 26 February 2026 meeting, EMA CHMP issued a positive opinion under exceptional circumstances for mavorixafor in WHIM syndrome, based on randomized placebo-controlled evidence in 31 patients and a constrained but decision-relevant clinical signal.
AbangeLabs